<?xml version='1.0' encoding='utf-8'?>
<document id="24726680"><sentence text="Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants."><entity charOffset="11-30" id="DDI-PubMed.24726680.s1.e0" text="hydrochlorothiazide" /><entity charOffset="94-107" id="DDI-PubMed.24726680.s1.e1" text="canagliflozin" /><entity charOffset="111-125" id="DDI-PubMed.24726680.s1.e2" text="sodium glucose" /><pair ddi="false" e1="DDI-PubMed.24726680.s1.e0" e2="DDI-PubMed.24726680.s1.e0" /><pair ddi="false" e1="DDI-PubMed.24726680.s1.e0" e2="DDI-PubMed.24726680.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24726680.s1.e0" e2="DDI-PubMed.24726680.s1.e2" /><pair ddi="false" e1="DDI-PubMed.24726680.s1.e1" e2="DDI-PubMed.24726680.s1.e1" /><pair ddi="false" e1="DDI-PubMed.24726680.s1.e1" e2="DDI-PubMed.24726680.s1.e2" /></sentence><sentence text="Many patients with type 2 diabetes mellitus (T2DM) also have hypertension, which is commonly treated with thiazide diuretics, including hydrochlorothiazide (HCTZ)"><entity charOffset="106-114" id="DDI-PubMed.24726680.s2.e0" text="thiazide" /><entity charOffset="136-155" id="DDI-PubMed.24726680.s2.e1" text="hydrochlorothiazide" /><entity charOffset="157-161" id="DDI-PubMed.24726680.s2.e2" text="HCTZ" /><pair ddi="false" e1="DDI-PubMed.24726680.s2.e0" e2="DDI-PubMed.24726680.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24726680.s2.e0" e2="DDI-PubMed.24726680.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24726680.s2.e0" e2="DDI-PubMed.24726680.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24726680.s2.e1" e2="DDI-PubMed.24726680.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24726680.s2.e1" e2="DDI-PubMed.24726680.s2.e2" /></sentence><sentence text=" Canagliflozin, a sodium glucose cotransporter 2 inhibitor developed for the treatment of T2DM, lowers plasma glucose by inhibiting renal glucose reabsorption, thereby increasing urinary glucose excretion and mild osmotic diuresis"><entity charOffset="1-14" id="DDI-PubMed.24726680.s3.e0" text="Canagliflozin" /><entity charOffset="18-32" id="DDI-PubMed.24726680.s3.e1" text="sodium glucose" /><entity charOffset="110-117" id="DDI-PubMed.24726680.s3.e2" text="glucose" /><entity charOffset="138-145" id="DDI-PubMed.24726680.s3.e3" text="glucose" /><entity charOffset="187-194" id="DDI-PubMed.24726680.s3.e4" text="glucose" /><pair ddi="false" e1="DDI-PubMed.24726680.s3.e0" e2="DDI-PubMed.24726680.s3.e0" /><pair ddi="false" e1="DDI-PubMed.24726680.s3.e0" e2="DDI-PubMed.24726680.s3.e1" /><pair ddi="false" e1="DDI-PubMed.24726680.s3.e0" e2="DDI-PubMed.24726680.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24726680.s3.e0" e2="DDI-PubMed.24726680.s3.e3" /><pair ddi="false" e1="DDI-PubMed.24726680.s3.e0" e2="DDI-PubMed.24726680.s3.e4" /><pair ddi="false" e1="DDI-PubMed.24726680.s3.e1" e2="DDI-PubMed.24726680.s3.e1" /><pair ddi="false" e1="DDI-PubMed.24726680.s3.e1" e2="DDI-PubMed.24726680.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24726680.s3.e1" e2="DDI-PubMed.24726680.s3.e3" /><pair ddi="false" e1="DDI-PubMed.24726680.s3.e1" e2="DDI-PubMed.24726680.s3.e4" /><pair ddi="false" e1="DDI-PubMed.24726680.s3.e2" e2="DDI-PubMed.24726680.s3.e2" /><pair ddi="false" e1="DDI-PubMed.24726680.s3.e2" e2="DDI-PubMed.24726680.s3.e3" /><pair ddi="false" e1="DDI-PubMed.24726680.s3.e2" e2="DDI-PubMed.24726680.s3.e4" /><pair ddi="false" e1="DDI-PubMed.24726680.s3.e3" e2="DDI-PubMed.24726680.s3.e3" /><pair ddi="false" e1="DDI-PubMed.24726680.s3.e3" e2="DDI-PubMed.24726680.s3.e4" /></sentence><sentence text=" Because patients with T2DM are likely to receive concurrent canagliflozin and HCTZ, potential interactions were evaluated"><entity charOffset="61-74" id="DDI-PubMed.24726680.s4.e0" text="canagliflozin" /><entity charOffset="79-91" id="DDI-PubMed.24726680.s4.e1" text="HCTZ" /><pair ddi="false" e1="DDI-PubMed.24726680.s4.e0" e2="DDI-PubMed.24726680.s4.e0" /><pair ddi="false" e1="DDI-PubMed.24726680.s4.e0" e2="DDI-PubMed.24726680.s4.e1" /></sentence><sentence text="" /><sentence text="This study evaluated the effects of HCTZ on the pharmacokinetic and pharmacodynamic properties and tolerability of canagliflozin in healthy participants"><entity charOffset="115-128" id="DDI-PubMed.24726680.s6.e0" text="canagliflozin" /><entity charOffset="36-48" id="DDI-PubMed.24726680.s6.e1" text="HCTZ" /><pair ddi="false" e1="DDI-PubMed.24726680.s6.e1" e2="DDI-PubMed.24726680.s6.e1" /><pair ddi="false" e1="DDI-PubMed.24726680.s6.e1" e2="DDI-PubMed.24726680.s6.e0" /></sentence><sentence text="" /><sentence text="This Phase I, single-center, open-label, fixed-sequence, 2-period study was conducted in healthy participants" /><sentence text=" During period 1, participants received canagliflozin 300 mg once daily for 7 days, followed by a 14-day washout period" /><sentence text=" During period 2, participants received HCTZ 25 mg once daily for 28 days, followed by canagliflozin 300 mg + HCTZ 25 mg once daily for 7 days"><entity charOffset="87-100" id="DDI-PubMed.24726680.s10.e0" text="canagliflozin" /><entity charOffset="40-52" id="DDI-PubMed.24726680.s10.e1" text="HCTZ" /><entity charOffset="110-122" id="DDI-PubMed.24726680.s10.e2" text="HCTZ" /><pair ddi="false" e1="DDI-PubMed.24726680.s10.e1" e2="DDI-PubMed.24726680.s10.e1" /><pair ddi="false" e1="DDI-PubMed.24726680.s10.e1" e2="DDI-PubMed.24726680.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24726680.s10.e1" e2="DDI-PubMed.24726680.s10.e2" /><pair ddi="false" e1="DDI-PubMed.24726680.s10.e0" e2="DDI-PubMed.24726680.s10.e0" /><pair ddi="false" e1="DDI-PubMed.24726680.s10.e0" e2="DDI-PubMed.24726680.s10.e2" /></sentence><sentence text=" Blood samples were taken before and several times after administration on day 7 of period 1 and on days 28 and 35 of period 2 for canagliflozin and HCTZ pharmacokinetic analyses using LC-MS/MS"><entity charOffset="131-144" id="DDI-PubMed.24726680.s11.e0" text="canagliflozin" /><entity charOffset="149-161" id="DDI-PubMed.24726680.s11.e1" text="HCTZ" /><pair ddi="false" e1="DDI-PubMed.24726680.s11.e0" e2="DDI-PubMed.24726680.s11.e0" /><pair ddi="false" e1="DDI-PubMed.24726680.s11.e0" e2="DDI-PubMed.24726680.s11.e1" /></sentence><sentence text=" Blood and urine samples were collected for up to 24 hours after canagliflozin administration on day 1 of period 1 and day 35 of period 2 for pharmacodynamic glucose assessment"><entity charOffset="158-165" id="DDI-PubMed.24726680.s12.e0" text="glucose" /></sentence><sentence text=" Tolerability was also evaluated" /><sentence text="" /><sentence text="Thirty participants were enrolled (16 men, 14 women; all white; mean age, 43" /><sentence text="7 years)" /><sentence text=" Canagliflozin AUC during a dosing interval (T) at steady state (AUCτ,ss) and Cmax at steady state (Cmax,ss) were increased when canagliflozin was coadministered with HCTZ, with geometric mean ratios (90% CI) of 1"><entity charOffset="129-142" id="DDI-PubMed.24726680.s17.e0" text="canagliflozin" /><entity charOffset="167-179" id="DDI-PubMed.24726680.s17.e1" text="HCTZ" /><pair ddi="false" e1="DDI-PubMed.24726680.s17.e0" e2="DDI-PubMed.24726680.s17.e0" /><pair ddi="false" e1="DDI-PubMed.24726680.s17.e0" e2="DDI-PubMed.24726680.s17.e1" /></sentence><sentence text="12 (1" /><sentence text="08-1" /><sentence text="17) and 1" /><sentence text="15 (1" /><sentence text="06-1" /><sentence text="25), respectively" /><sentence text=" AUCτ,ss and Cmax,ss for HCTZ were similar with and without canagliflozin coadministration"><entity charOffset="60-73" id="DDI-PubMed.24726680.s24.e0" text="canagliflozin" /><entity charOffset="25-37" id="DDI-PubMed.24726680.s24.e1" text="HCTZ" /><pair ddi="false" e1="DDI-PubMed.24726680.s24.e1" e2="DDI-PubMed.24726680.s24.e1" /><pair ddi="false" e1="DDI-PubMed.24726680.s24.e1" e2="DDI-PubMed.24726680.s24.e0" /></sentence><sentence text=" The 24-hour mean renal threshold for glucose and mean plasma glucose were comparable for canagliflozin alone and coadministered with HCTZ"><entity charOffset="38-45" id="DDI-PubMed.24726680.s25.e0" text="glucose" /><entity charOffset="62-69" id="DDI-PubMed.24726680.s25.e1" text="glucose" /><entity charOffset="90-103" id="DDI-PubMed.24726680.s25.e2" text="canagliflozin" /><entity charOffset="134-146" id="DDI-PubMed.24726680.s25.e3" text="HCTZ" /><pair ddi="false" e1="DDI-PubMed.24726680.s25.e0" e2="DDI-PubMed.24726680.s25.e0" /><pair ddi="false" e1="DDI-PubMed.24726680.s25.e0" e2="DDI-PubMed.24726680.s25.e1" /><pair ddi="false" e1="DDI-PubMed.24726680.s25.e0" e2="DDI-PubMed.24726680.s25.e2" /><pair ddi="false" e1="DDI-PubMed.24726680.s25.e0" e2="DDI-PubMed.24726680.s25.e3" /><pair ddi="false" e1="DDI-PubMed.24726680.s25.e1" e2="DDI-PubMed.24726680.s25.e1" /><pair ddi="false" e1="DDI-PubMed.24726680.s25.e1" e2="DDI-PubMed.24726680.s25.e2" /><pair ddi="false" e1="DDI-PubMed.24726680.s25.e1" e2="DDI-PubMed.24726680.s25.e3" /><pair ddi="false" e1="DDI-PubMed.24726680.s25.e2" e2="DDI-PubMed.24726680.s25.e2" /><pair ddi="false" e1="DDI-PubMed.24726680.s25.e2" e2="DDI-PubMed.24726680.s25.e3" /></sentence><sentence text=" The change in 24-hour urine volume from baseline was -0" /><sentence text="1 L with canagliflozin alone and 0"><entity charOffset="9-22" id="DDI-PubMed.24726680.s27.e0" text="canagliflozin" /></sentence><sentence text="4 L with HCTZ alone and with canagliflozin + HCTZ"><entity charOffset="9-21" id="DDI-PubMed.24726680.s28.e0" text="HCTZ" /><entity charOffset="45-57" id="DDI-PubMed.24726680.s28.e1" text="HCTZ" /><pair ddi="false" e1="DDI-PubMed.24726680.s28.e0" e2="DDI-PubMed.24726680.s28.e0" /><pair ddi="false" e1="DDI-PubMed.24726680.s28.e0" e2="DDI-PubMed.24726680.s28.e1" /></sentence><sentence text=" The overall incidence of adverse events (AEs) was higher with canagliflozin + HCTZ (69%) than with canagliflozin (47%) or HCTZ (50%) alone; most AEs were of mild severity"><entity charOffset="100-113" id="DDI-PubMed.24726680.s29.e0" text="canagliflozin" /><entity charOffset="123-127" id="DDI-PubMed.24726680.s29.e1" text="HCTZ" /><entity charOffset="79-82" id="DDI-PubMed.24726680.s29.e2" text="HCTZ" /><pair ddi="false" e1="DDI-PubMed.24726680.s29.e2" e2="DDI-PubMed.24726680.s29.e2" /><pair ddi="false" e1="DDI-PubMed.24726680.s29.e2" e2="DDI-PubMed.24726680.s29.e0" /><pair ddi="false" e1="DDI-PubMed.24726680.s29.e2" e2="DDI-PubMed.24726680.s29.e1" /><pair ddi="false" e1="DDI-PubMed.24726680.s29.e0" e2="DDI-PubMed.24726680.s29.e0" /><pair ddi="false" e1="DDI-PubMed.24726680.s29.e0" e2="DDI-PubMed.24726680.s29.e1" /></sentence><sentence text=" Overall, minimal changes in serum electrolytes (eg, sodium, potassium) were observed after coadministration of canagliflozin + HCTZ compared with individual treatments"><entity charOffset="53-59" id="DDI-PubMed.24726680.s30.e0" text="sodium" /><entity charOffset="61-70" id="DDI-PubMed.24726680.s30.e1" text="potassium" /><entity charOffset="112-132" id="DDI-PubMed.24726680.s30.e2" text="canagliflozin + HCTZ" /><entity charOffset="128-147" id="DDI-PubMed.24726680.s30.e3" text="HCTZ" /><pair ddi="false" e1="DDI-PubMed.24726680.s30.e0" e2="DDI-PubMed.24726680.s30.e0" /><pair ddi="false" e1="DDI-PubMed.24726680.s30.e0" e2="DDI-PubMed.24726680.s30.e1" /><pair ddi="false" e1="DDI-PubMed.24726680.s30.e0" e2="DDI-PubMed.24726680.s30.e2" /><pair ddi="false" e1="DDI-PubMed.24726680.s30.e0" e2="DDI-PubMed.24726680.s30.e3" /><pair ddi="false" e1="DDI-PubMed.24726680.s30.e1" e2="DDI-PubMed.24726680.s30.e1" /><pair ddi="false" e1="DDI-PubMed.24726680.s30.e1" e2="DDI-PubMed.24726680.s30.e2" /><pair ddi="false" e1="DDI-PubMed.24726680.s30.e1" e2="DDI-PubMed.24726680.s30.e3" /><pair ddi="false" e1="DDI-PubMed.24726680.s30.e2" e2="DDI-PubMed.24726680.s30.e2" /><pair ddi="false" e1="DDI-PubMed.24726680.s30.e2" e2="DDI-PubMed.24726680.s30.e3" /></sentence><sentence text="" /><sentence text="Adding canagliflozin treatment to healthy participants on HCTZ treatment had no notable pharmacokinetic or pharmacodynamic effects; canagliflozin coadministered with HCTZ was generally well tolerated, with no unexpected tolerability concerns"><entity charOffset="7-20" id="DDI-PubMed.24726680.s32.e0" text="canagliflozin" /><entity charOffset="132-145" id="DDI-PubMed.24726680.s32.e1" text="canagliflozin" /><entity charOffset="58-70" id="DDI-PubMed.24726680.s32.e2" text="HCTZ" /><entity charOffset="166-178" id="DDI-PubMed.24726680.s32.e3" text="HCTZ" /><pair ddi="false" e1="DDI-PubMed.24726680.s32.e0" e2="DDI-PubMed.24726680.s32.e0" /><pair ddi="false" e1="DDI-PubMed.24726680.s32.e0" e2="DDI-PubMed.24726680.s32.e2" /><pair ddi="false" e1="DDI-PubMed.24726680.s32.e0" e2="DDI-PubMed.24726680.s32.e1" /><pair ddi="false" e1="DDI-PubMed.24726680.s32.e0" e2="DDI-PubMed.24726680.s32.e3" /><pair ddi="false" e1="DDI-PubMed.24726680.s32.e2" e2="DDI-PubMed.24726680.s32.e2" /><pair ddi="false" e1="DDI-PubMed.24726680.s32.e2" e2="DDI-PubMed.24726680.s32.e1" /><pair ddi="false" e1="DDI-PubMed.24726680.s32.e2" e2="DDI-PubMed.24726680.s32.e3" /><pair ddi="false" e1="DDI-PubMed.24726680.s32.e1" e2="DDI-PubMed.24726680.s32.e1" /><pair ddi="false" e1="DDI-PubMed.24726680.s32.e1" e2="DDI-PubMed.24726680.s32.e3" /></sentence><sentence text=" ClinicalTrials" /><sentence text="gov identifier: NCT01294631" /><sentence text="" /></document>